Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective

Journal of Alzheimer's Disease

Volumn 69, Issue 3, 2019, Pages 615-629

  Hampel, Harald ^a   Lista, Simone ^a,b,c   Mango, Dalila ^d   Nisticò, Robert ^d,e   Perry, George ^f   Avila, Jesus ^g,h   Hernandez, Felix ^g,h   Geerts, Hugo ⁱ   Vergallo, Andrea ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f University of San Antonio   (United States)

^g UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^h CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

ⁱ In Silico Biosciences   (United States)

Author keywords

Alzheimer's disease; GSK3; lithium; neurotoxicity; post translational modification; precision medicine; systems pharmacology; tau

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; LITHIUM CHLORIDE; TRANQUILIZER;

ALZHEIMER DISEASE; ANIMAL MODEL; DRUG REPOSITIONING; HUMAN; MOLECULAR EVOLUTION; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECT; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; ANTIMANIC AGENTS; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; LITHIUM CHLORIDE; METABOLIC NETWORKS AND PATHWAYS;

EID: 85067111942     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-190197     Document Type: Review

References (104)

1. Shine JM, Breakspear M, Bell PT, Ehgoetz Martens KA, Shine R, Koyejo O, Sporns O, Poldrack RA (2019) Human cognition involves the dynamic integration of neural activity and neuromodulatory systems. Nat Neurosci 22, 289-296.
2. Palop JJ, Mucke L (2016) Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat Rev Neurosci 17, 777.
3. Henstridge CM, Hyman BT, Spires-Jones TL (2019) Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis. Nat Rev Neurosci 20, 94-108.
4. Hoeijmakers JHJ (2009) DNA damage, aging, and cancer. N Engl J Med 361, 1475-1485.
5. Hampel H, Toschi N, Babiloni C, Baldacci F, Black KL, Bokde ALW, Bun RS, Cacciola F, Cavedo E, Chiesa PA, Colliot O, Coman C-M, Dubois B, Duggento A, Durrleman S, Ferretti M-T, George N, Genthon R, Habert M-O, Herholz K, Koronyo Y, Koronyo-Hamaoui M, Lamari F, Langevin T, Lehericy S, Lorenceau J, Neri C, Nistico R, Nyasse-Messene F, Ritchie C, Rossi S, Santarnecchi E, Sporns O, Verdooner SR, Vergallo A, Villain N, Younesi E, Garaci F, Lista S (2018) Revolution of Alzheimer Precision Neurology. Passageway of systems biology and neurophysiology. J Alzheimers Dis 64, S47-S105.
6. Cummings JL, Tong G, Ballard C (2019) Treatment combinations for Alzheimer's disease: Current and future pharmacotherapy options. J Alzheimers Dis 67, 779-794.
7. Roberts PD, Spiros A, Geerts H (2012) Simulations of symptomatic treatments for Alzheimer's disease: Computational analysis of pathology and mechanisms of drug action. Alzheimers Res Ther 4, 50.
8. Harrold JM, Ramanathan M, Mager DE (2013) Networkbased approaches in drug discovery and early development. Clin Pharmacol Ther 94, 651-658.
9. Richiardi J, Altmann A, Milazzo A-C, Chang C, Chakravarty MM, Banaschewski T, Barker GJ, Bokde ALW, Bromberg U, Buchel C, Conrod P, Fauth-Buhler M, Flor H, Frouin V, Gallinat J, Garavan H, Gowland P, Heinz A, Lemaitre H, Mann KF, Martinot J-L, Nees F, Paus T, Pausova Z, Rietschel M, Robbins TW, Smolka MN, Spanagel R, Strohle A, Schumann G, Hawrylycz M, Poline J-B, Greicius MD (2015) BRAIN NETWORKS. Correlated gene expression supports synchronous activity in brain networks. Science 348, 1241-1244.
10. Lyu J, Wang S, Balius TE, Singh I, Levit A, Moroz YS, O'Meara MJ, Che T, Algaa E, Tolmachova K, Tolmachev AA, Shoichet BK, Roth BL, Irwin JJ (2019) Ultra-large library docking for discovering new chemotypes. Nature 566, 224-229.
11. Zhao S, Iyengar R (2012) Systems pharmacology: Network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol 52, 505-521.
12. Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Woodcock J, Baldacci F, Lista S (2018) Precision pharmacology for Alzheimer's disease. Pharmacol Res 130, 331-365.
13. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, BoniV, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM (2018) Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378, 731-739.
14. Deng X, Nakamura Y (2017) Cancer precision medicine: From cancer screening to drug selection and personalized immunotherapy. Trends Pharmacol Sci 38, 15-24.
15. Power A, Berger AC, Ginsburg GS (2014) Genomicsenabled drug repositioning and repurposing: Insights from an IOM Roundtable activity. JAMA 311, 2063-2064.
16. Hampel H, O'Bryant SE, Durrleman S, Younesi E, Rojkova K, Escott-Price V, Corvol J-C, Broich K, Dubois B, Lista S (2017) A Precision Medicine Initiative for Alzheimer's disease: The road ahead to biomarker-guided integrative disease modeling. Climacteric 20, 107-118.
17. Perez-Nievas BG, Stein TD, Tai H-C, Dols-Icardo O, Scotton TC, Barroeta-Espar I, Fernandez-Carballo L, de Munain EL, Perez J, Marquie M, Serrano-Pozo A, Frosch MP, Lowe V, Parisi JE, Petersen RC, Ikonomovic MD, Lopez OL, Klunk W, Hyman BT, Gomez-Isla T (2013) Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain 136, 2510-2526.
18. Scheller E, Schumacher LV, Peter J, Lahr J, Wehrle J, Kaller CP, Gaser C, Kloppel S (2018) Brain aging and APOE epsilon4 interact to reveal potential neuronal compensation in healthy older adults. Front Aging Neurosci 10, 74.
19. Seeley WW (2011) Divergent network connectivity changes in healthy APOE epsilon4 carriers: Disinhibition or compensation? Arch Neurol 68, 1107-1108.
20. Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, Kiddle SJ, Batrla R, Blennow K (2018) Blood-based biomarkers for Alzheimer disease: Mapping the road to the clinic. Nat Rev Neurol 14, 639-652.
21. Alda M (2015) Lithium in the treatment of bipolar disorder: Pharmacology and pharmacogenetics. Mol Psychiatry 20, 661-670.
22. Matsunaga S, Kishi T, Annas P, Basun H, Hampel H, Iwata N (2015) Lithium as a treatment for Alzheimer's disease: A systematic review and meta-analysis. J Alzheimers Dis 48, 403-410.
23. Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A, Frolich L, Schroder J, Schonknecht P, Riepe MW, Kraft I, Gasser T, Leyhe T, Moller H-J, Kurz A, Basun H (2009) Lithium trial in Alzheimer's disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 70, 922-931.
24. Tariot PN, Aisen PS (2009) Can lithium or valproate untie tangles in Alzheimer's disease? J Clin Psychiatry 70, 919-921.
25. Forlenza OV, Aprahamian I, de Paula VJ, Hajek T (2016) Lithium, a therapy for AD: Current evidence from clinical trials of neurodegenerative disorders. Curr Alzheimer Res 13, 879-886.
26. Kerr F, Bjedov I, Sofola-Adesakin O (2018) Molecular mechanisms of lithium action: Switching the light on multiple targets for dementia using animal models. Front Mol Neurosci 11, 297.
27. Freland L, Beaulieu J-M (2012) Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci 5, 14.
28. Braak H, Zetterberg H, Del Tredici K, Blennow K (2013) Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-beta changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol 126, 631-641.
29. Panza F, Lozupone M, Logroscino G, Imbimbo BP (2019) Acritical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat Rev Neurol 15, 73-88.
30. Behl C (2017) Amyloid in Alzheimer's disease: Guilty beyond reasonable doubt? Trends Pharmacol Sci 38, 849-851.
31. Congdon EE, Sigurdsson EM (2018) Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol 14, 399-415.
32. Cardillo G de M, De-Paula V de JR, Ikenaga EH, Costa LR, Catanozi S, Schaeffer EL, Gattaz WF, Kerr DS, Forlenza OV (2018) Chronic lithium treatment increases telomere length in parietal cortex and hippocampus of triple-transgenic Alzheimer's disease mice. J Alzheimers Dis 63, 93-101.
33. Zhao L, Gong N, Liu M, Pan X, Sang S, Sun X, Yu Z, Fang Q, Zhao N, Fei G, Jin L, Zhong C, Xu T (2014) Beneficial synergistic effects of microdose lithium with pyrroloquinoline quinone in an Alzheimer's disease mouse model. Neurobiol Aging 35, 2736-2745.
34. Machado-Vieira R (2018) Lithium, stress, and resilience in bipolar disorder: Deciphering this key homeostatic synaptic plasticity regulator. J Affect Disord 233, 92-99.
35. Nistico R, Pignatelli M, Piccinin S, Mercuri NB, Collingridge G (2012) Targeting synaptic dysfunction in Alzheimer's disease therapy. Mol Neurobiol 46, 572-587.
36. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791.
37. Nisticò R., Collingridge G (2012) The synaptic basis of Alzheimer's disease. Eur J Neurodegener Dis 1, 21-33
38. Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R (2002) Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 22, RC221.
39. Townsend M, Mehta T, Selkoe DJ (2007) Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282, 33305-33312.
40. Cohen P, Frame S (2001) The renaissance of GSK3. Nat Rev Mol Cell Biol 2, 769-776.
41. Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104, 1433-1439.
42. Baki L, Shioi J, Wen P, Shao Z, Schwarzman A, Gama-Sosa M, Neve R, Robakis NK (2004) PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: Effects of FAD mutations. EMBO J 23, 2586-2596.
43. Magdesian MH, Carvalho MMVF, Mendes FA, Saraiva LM, Juliano MA, Juliano L, Garcia-Abreu J, Ferreira ST (2008) Amyloid-beta binds to the extracellular cysteinerich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J Biol Chem 283, 9359-9368.
44. Hernandez F, Lucas JJ, Avila J (2013) GSK3 and tau: Two convergence points in Alzheimer's disease. J Alzheimers Dis 33(Suppl 1), S141-144.
45. Kimura T, Yamashita S, Nakao S, Park J-M, Murayama M, Mizoroki T, Yoshiike Y, Sahara N, Takashima A (2008) GSK-3beta is required for memory reconsolidation in adult brain. PLoS One 3, e3540.
46. Bhat R V, Budd Haeberlein SL, Avila J (2004) Glycogen synthase kinase 3: A drug target for CNS therapies. J Neurochem 89, 1313-1317.
47. Jope RS, Yuskaitis CJ, Beurel E (2007) Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics. Neurochem Res 32, 577-595.
48. Jo J, Whitcomb DJ, Olsen KM, Kerrigan TL, Lo SC, Bru-Mercier G, Dickinson B, Scullion S, Sheng M, Collingridge G, Cho K (2011) Abeta(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3beta. Nat Neurosci 14, 545-547.
49. Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T, Hernandez F, Anderton B, Rosenblum K, Bliss T, Cooke SF, Avila J, Lucas JJ, Giese KP, Stephenson J, Lovestone S (2007) Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 25, 81-86.
50. Shipton OA, Leitz JR, Dworzak J, Acton CEJ, Tunbridge EM, Denk F, Dawson HN, Vitek MP, Wade-Martins R, Paulsen O, Vargas-Caballero M (2011) Tau protein is required for amyloid beta-induced impairment of hippocampal long-term potentiation. J Neurosci 31, 1688-1692.
51. Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, Tampellini D, Klann E, Blitzer RD, Gouras GK (2010) Dysregulation of themTORpathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS One 5, e12845.
52. Schaeffer EL, Catanozi S, West MJ, Gattaz WF (2017) Stereological investigation of theCA1pyramidal cell layer in untreated and lithium-treated 3xTg-AD and wild-type mice. Ann Anat 209, 51-60.
53. Zhang X, Heng X, Li T, Li L, Yang D, Zhang X, Du Y, Doody RS, Le W (2011) Long-term treatment with lithium alleviates memory deficits and reduces amyloid-beta production in an aged Alzheimer's disease transgenic mouse model. J Alzheimers Dis 24, 739-749.
54. Habib A, Sawmiller D, Li S, Xiang Y, Rongo D, Tian J, Hou H, Zeng J, Smith A, Fan S, Giunta B, Mori T, Currier G, Shytle DR, Tan J (2017) LISPRO mitigates beta-amyloid and associated pathologies in Alzheimer's mice. Cell Death Dis 8, e2880.
55. Plattner F, Angelo M, Giese KP (2006) The roles of cyclindependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 281, 25457-25465.
56. Ishiguro K, Shiratsuchi A, Sato S, Omori A, Arioka M, Kobayashi S, Uchida T, Imahori K (1993) Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett 325, 167-172.
57. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R (2004) Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24, 3370-3378.
58. Butler D, Bendiske J, Michaelis ML, Karanian DA, Bahr BA (2007) Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers. Eur J Pharmacol 562, 20-27.
59. Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2, a006346.
60. Fuster-Matanzo A, Jurado-Arjona J, Benvegnu S, Garcia E, Martin-Maestro P, Gomez-Sintes R, Hernandez F, Avila J (2017) Glycogen synthase kinase-3beta regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: Implications for Alzheimer's disease. Cell Mol Life Sci 74, 1153-1163.
61. Arranz AM, De Strooper B (2019) The role of astroglia in Alzheimer's disease: Pathophysiology and clinical implications. Lancet Neurol 18, 406-414.
62. King MK, Pardo M, Cheng Y, Downey K, Jope RS, Beurel E (2014) Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments. Pharmacol Ther 141, 1-12.
63. Martinez A, Gil C, Perez DI (2011) Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment. Int J Alzheimers Dis 2011, 280502.
64. Hernandez F, Borrell J, Guaza C, Avila J, Lucas JJ (2002) Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem 83, 1529-1533.
65. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20, 27-39.
66. Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F (2006) Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 99, 1445-1455.
67. Engel T, Hernandez F, Avila J, Lucas JJ (2006) Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 26, 5083-5090.
68. Gomez de Barreda E, Perez M, Gomez Ramos P, de Cristobal J, Martin-Maestro P, Moran A, Dawson HN, Vitek MP, Lucas JJ, Hernandez F, Avila J (2010) Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol Dis 37, 622-629.
69. Nakashima H, Ishihara T, Suguimoto P, Yokota O, Oshima E, Kugo A, Terada S, Hamamura T, Trojanowski JQ, Lee VM-Y, Kuroda S (2005) Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol 110, 547-556.
70. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102, 6990-6995.
71. Perez M, Hernandez F, Lim F, Diaz-Nido J, Avila J (2003) Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 5, 301-308.
72. Sudduth TL, Wilson JG, Everhart A, Colton CA, Wilcock DM (2012) Lithium treatment of APPSwDI/NOS2-/-mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype. PLoS One 7, e31993.
73. Lei P, Ayton S, Appukuttan AT, Moon S, Duce JA, Volitakis I, Cherny R, Wood SJ, Greenough M, Berger G, Pantelis C, McGorry P, Yung A, Finkelstein DI, Bush AI (2017) Lithium suppression of tau induces brain iron accumulation and neurodegeneration. Mol Psychiatry 22, 396-406.
74. Jurado-Arjona J, Llorens-Martin M, Avila J, Hernandez F (2016) GSK3beta overexpression in dentate gyrus neural precursor cells expands the progenitor pool and enhances memory skills. J Biol Chem 291, 8199-8213.
75. Jurado-Arjona J, Rodriguez-Matellan A, Avila J, Hernandez F (2019) GSK3beta overexpression driven by GFAP promoter improves rotarod performance. Brain Res 1712, 47-54.
76. Nunes MA, Schowe NM, Monteiro-Silva KC, Baraldi-Tornisielo T, Souza SIG, Balthazar J, Albuquerque MS, Caetano AL, Viel TA, Buck HS (2015) Chronic microdose lithium treatment prevented memory loss and neurohistopathological changes in a transgenic mouse model of Alzheimer's disease. PLoS One 10, e0142267.
77. Wilson EN, Do Carmo S, Iulita MF, Hall H, Ducatenzeiler A, Marks AR, Allard S, Jia DT, Windheim J, Cuello AC (2017) BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology. Transl Psychiatry 7, e1190.
78. Grunfeld J-P, Rossier BC (2009) Lithium nephrotoxicity revisited. Nat Rev Nephrol 5, 270-276.
79. Jing P, Zhang J-Y, Ouyang Q, Wu J, Zhang X-J (2013) Lithium treatment induces proteasomal degradation of over-expressed acetylcholinesterase (AChE-S) and inhibit GSK3beta. Chem Biol Interact 203, 309-313.
80. Hampel H, Mesulam M-M, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ, Khachaturian ZS (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain 141, 1917-1933.
81. Credle JJ, George JL, Wills J, Duka V, Shah K, Lee Y-C, Rodriguez O, Simkins T, Winter M, Moechars D, Steckler T, Goudreau J, Finkelstein DI, Sidhu A (2015) GSK-3beta dysregulation contributes to Parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and alpha-synuclein. Cell Death Differ 22, 838-851.
82. Gassowska M, Czapski GA, Pajak B, Cieslik M, Lenkiewicz AM, Adamczyk A (2014) Extracellular alpha-synuclein leads to microtubule destabilization via GSK-3beta-dependent Tau phosphorylation in PC12 cells. PLoS One 9, e94259.
83. Nubling G, Bader B, Levin J, Hildebrandt J, Kretzschmar H, Giese A (2012) Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with alpha-synuclein at the single molecule level. Mol Neurodegener 7, 35.
84. Fontana L, Partridge L, Longo VD (2010) Extending healthy life span-from yeast to humans. Science 328, 321-326.
85. Childs BG, Durik M, Baker DJ, van Deursen JM (2015) Cellular senescence in aging and age-related disease: From mechanisms to therapy. Nat Med 21, 1424-1435.
86. Hampel H, Lista S, Khachaturian ZS (2012) Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement 8, 312-336.
87. Augustinack JC, Schneider A, Mandelkow E-M, Hyman BT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103, 26-35.
88. Liu F, Liang Z, Shi J, Yin D, El-Akkad E, Grundke-Iqbal I, Iqbal K, Gong C-X (2006) PKA modulates GSK-3betaand cdk5-catalyzed phosphorylation of tau in site-and kinase-specific manners. FEBS Lett 580, 6269-6274.
89. Hanger DP, Byers HL, Wray S, Leung K-Y, Saxton MJ, Seereeram A, Reynolds CH, Ward MA, Anderton BH (2007) Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 282, 23645-23654.
90. Feijoo C, Campbell DG, Jakes R, Goedert M, Cuenda A (2005) Evidence that phosphorylation of the microtubuleassociated protein Tau by SAPK4/p38delta at Thr50 promotes microtubule assembly. J Cell Sci 118, 397-408.
91. Rubenstein R, Chang B, Davies P, Wagner AK, Robertson CS, Wang KKW (2015) A novel, ultrasensitive assay for tau: Potential for assessing traumatic brain injury in tissues and biofluids. J Neurotrauma 32, 342-352.
92. Zhou Y, Shi J, Chu D, HuW, Guan Z, Gong C-X, Iqbal K, Liu F (2018) Relevance of phosphorylation and truncation of tau to the etiopathogenesis of Alzheimer's disease.Front Aging Neurosci 10, 27.
93. Xia D, Li C, Gotz J (2015) Pseudophosphorylation of tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein tau to dendritic spines. Biochim Biophys Acta 1852, 913-924.
94. Mair W, Muntel J, Tepper K, Tang S, Biernat J, Seeley WW, Kosik KS, Mandelkow E, Steen H, Steen JA (2016) FLEXITau: Quantifying post-translational modifications of tau protein in vitro and in human disease. Anal Chem 88, 3704-3714.
95. Hampel H, Buerger K, Kohnken R, Teipel SJ, Zinkowski R, Moeller HJ, Rapoport SI, Davies P (2001) Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann Neurol 49, 545-546.
96. Morris M, Knudsen GM, Maeda S, Trinidad JC, Ioanoviciu A, Burlingame AL, Mucke L (2015) Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci 18, 1183-1189.
97. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129, 3035-3041.
98. Stepanov A, Karelina T, Markevich N, Demin O, Nicholas T (2018) A mathematical model of multisite phosphorylation of tau protein. PLoS One 13, e0192519.
99. Liu SJ, Zhang JY, Li HL, Fang ZY, Wang Q, Deng HM, Gong CX, Grundke-Iqbal I, Iqbal K, Wang JZ (2004) Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. J Biol Chem 279, 50078-50088.
100. Singh SA, Winter D, Bilimoria PM, Bonni A, Steen H, Steen JA (2012) FLEXIQinase, a mass spectrometrybased assay, to unveil multikinase mechanisms. Nat Methods 9, 504-508.
101. Liu F, Grundke-Iqbal I, Iqbal K, Gong C-X (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22, 1942-1950.
102. Geerts H, Spiros A, Roberts P, Carr R (2013) Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development. J Pharmacokinet Pharmacodyn 40, 257-265.
103. Geerts H, Spiros A, Roberts P (2018) Impact of amyloidbeta changes on cognitive outcomes in Alzheimer's disease: Analysis of clinical trials using a quantitative systems pharmacology model. Alzheimers Res Ther 10, 14.
104. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde ALW, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K (2010) Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives. Nat Rev Drug Discov 9, 560-574.